Fund managers including Saville Capital and Sandon Capital have invested in IDT Australia Ltd (ASX:IDT).

Saville Capital highlights upgraded FY26 revenue and earnings guidance, strong growth in active pharmaceutical ingredient manufacturing, substantial cost reductions and director buying, which it sees as a sign of internal confidence that the share price undervalues the outlook.

Saville noted the business was still loss-making at the EBITDA level in the first half, though losses narrowed, and the shares fell 12% in one month, highlighting volatility for a small manufacturer still proving its turnaround.

IDT Australia Ltd is a pharmaceutical company specializing in the development and manufacturing of high-quality medicinal products. Established on October 14, 1975, by founder Graeme Leslie Blackman, the company maintains its corporate headquarters in Melbourne, Australia. IDT Australia provides comprehensive pharmaceutical services, leveraging decades of industry experience to support complex manufacturing requirements. The firm remains a key player in the Australian pharmaceutical sector, focusing on operational excellence and professional product development for global and domestic markets.